Cyclosporine before PCI in Patients with Acute Myocardial Infarction.

Authors :: Cung, T.-T.
Morel, O.
Cayla, G.
Rioufol, G.
Garcia-Dorado, D.
Angoulvant, D.
Bonnefoy-Cudraz, E.
Guérin, P.
Elbaz, M.
Delarche, N.
Coste, P.
Vanzetto, G.
Metge, M.
Aupetit, J.-F.
Jouve, B.
Motreff, P.
Tron, C.
Labeque, J.-N.
Steg, P. G.
Cottin, Y.
Source :: New England Journal of Medicine. 9/10/2015, Vol. 373 Issue 11, p1021-1031. 10p.
Publication Year :: 2015
Abstract: The article discusses a study that investigated the impact of the drug cyclosporine on patients with acute myocardial infarction. Under this study, 970 patients with an acute anterior ST-segment elevation myocardial infraction (STEMI) undergoing percutaneous coronary intervention (PCI) were given either a bolus injection of cyclosporine or matching placebo. Findings on patient outcomes and adverse events such as death, worsening heart failure and adverse left ventricular remodeling are tackled.